Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib

BJU International

Volumn 109, Issue 9, 2012, Pages 1349-1354

  Yuasa, Takeshi ^a,b   Tsuchiya, Norihiko ^b   Urakami, Shinji ^a   Horikawa, Yohei ^b   Narita, Shintaro ^b   Inoue, Takamitsu ^b   Saito, Mitsuru ^b   Yamamoto, Shinya ^a   Yonese, Junji ^a   Fukui, Iwao ^a   Nakano, Kenji ^a   Takahashi, Shunji ^a   Hatake, Kiyohiko ^a   Habuchi, Tomonori ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MSKCC score; Outcome; Prognostic factor; Renal cell cancer; Sunitinib

Indexed keywords

ALPHA INTERFERON; SORAFENIB; SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPANESE; KIDNEY CARCINOMA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC RENAL CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859813736     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10534.x     Document Type: Article

References (21)

1. Hutson TE, Figlin RA. Novel therapeutics for metastatic renal cell carcinoma. C ancer 2009; 115: 2361-7
2. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18: x3-10
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
4. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
5. Uemura H, Shinohara N, Yuasa T et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40: 194-202
6. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000; 92: 205-1
7. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. B r Med J 1973; 4: 643-6
8. Motzer RJ, Murphy BA, Bacik J, Russa P, Mazudmar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2001; 20: 289-96 (Pubitemid 34032623)
9. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-63 (Pubitemid 41079774)
10. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63
11. Tomita Y, Shinohara N, Yuasa T et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010; 40: 1166-72
12. Bamias A, Karadimou A, Lampaki S et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 2010; 10: 45
13. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110: 543-50 (Pubitemid 47106142)
14. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22: 295-300
15. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9
16. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-705 (Pubitemid 34478086)
17. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22: 2865-72 (Pubitemid 41079905)
18. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007; 18: 1282-3 (Pubitemid 47244377)
19. Zeng H, Li X, Yao J et al. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int 2009; 83: 482 -5
20. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9 (Pubitemid 33126820)
21. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-70